321 related articles for article (PubMed ID: 9723270)
1. Use of microemulsion form cyclosporine immediately after kidney transplantation without intravenous cyclosporine.
Jirasiritham S; Sumethkul V; Mavichak V; Jirasiritham S
Transplant Proc; 1998 Aug; 30(5):1760-1. PubMed ID: 9723270
[No Abstract] [Full Text] [Related]
2. Safety and effectiveness of microemulsion cyclosporine in renal allograft recipients: 1-year follow-up study.
Park K; Kim MS; Kim SI; Kim YS; Moon JI
Transplant Proc; 1998 Nov; 30(7):3556-7. PubMed ID: 9838557
[No Abstract] [Full Text] [Related]
3. Conversion to cyclosporine microemulsion (Neoral) in stable renal transplant patients: results from a single center.
Cossu M; Satta R; Branca GF; Pala PG; Serra G; Satta RP; Sorba G
Transplant Proc; 1998 Aug; 30(5):1762-3. PubMed ID: 9723271
[No Abstract] [Full Text] [Related]
4. Clinical safety and tolerability of microemulsion cyclosporine in stable renal transplant patients.
Gracida C; Melchor JL
Transplant Proc; 1996 Dec; 28(6):3379. PubMed ID: 8962318
[No Abstract] [Full Text] [Related]
5. Optimization of cyclosporine therapy in renal transplantation.
Ponticelli C
Transplant Proc; 1998 Aug; 30(5):1718-20. PubMed ID: 9723254
[No Abstract] [Full Text] [Related]
6. Acute allograft rejection following conversion to a new cyclosporine formulation in pediatric renal transplant patients.
Crocker J; Renton K; Wade A; McLellan H; Acott P
Transplant Proc; 1998 Aug; 30(5):2002-5. PubMed ID: 9723369
[No Abstract] [Full Text] [Related]
7. Clinical outcomes during the first three months posttransplant in renal allograft recipients managed by C2 monitoring of cyclosporine microemulsion.
Thervet E; Pfeffer P; Scolari MP; Toselli L; Pallardó LM; Chadban S; Pilmore H; Connolly J; Buchler M; Schena FP; Carreño CA; Dandavino R; Cole E
Transplantation; 2003 Sep; 76(6):903-8. PubMed ID: 14508352
[TBL] [Abstract][Full Text] [Related]
8. A critical appraisal of cyclosporine A pharmacokinetics in pediatric kidney transplantation using a microemulsion galenic formulation (Neoral).
Foradori A; Pinto VM; Elberg A
Transplant Proc; 1998 Aug; 30(5):1666-7. PubMed ID: 9723235
[No Abstract] [Full Text] [Related]
9. Conversion from conventional Sandimmun to Neoral therapy in stable renal transplant recipients.
Løkkegaard H; Asmundsson P; Clausen P; Dieperink H; Hansen JM; Heaf J; Jensen SB; Kornerup HJ; Madsen S; Pedersen EB; Poulsen JV; Rasmussen K
Transplant Proc; 1996 Aug; 28(4):2199-201. PubMed ID: 8769199
[No Abstract] [Full Text] [Related]
10. Cyclosporine from twice to single daily dosing: impact on renal function, mortality, and graft loss.
Bianco PD; Silva HT; Boni R; Machado PG; Pacheco-Silva A; Pestana JO
Transplant Proc; 2002 Nov; 34(7):2920-1. PubMed ID: 12431657
[No Abstract] [Full Text] [Related]
11. Evaluation of tolerability, safety, and efficacy of cyclosporine microemulsion in renal transplant recipients.
Gracida C; Melchor JL; Miranda ME; Bartolano C
Transplant Proc; 1996 Aug; 28(4):2171-3. PubMed ID: 8769191
[No Abstract] [Full Text] [Related]
12. Long-term results of conversion from existing to microemulsion formulation of cyclosporine.
Neumayer HH; Färber L; Budde K; Kohnen R; Maibücher A; Schuster A; Vollmar J; Waiser J; Luft FC
Transplant Proc; 1996 Aug; 28(4):2207-13. PubMed ID: 8769202
[No Abstract] [Full Text] [Related]
13. Microemulsion cyclosporine postmarketing surveillance in renal transplant recipients: multicenter study in Korea.
Korean Neoral Study Group
Transplant Proc; 2000 Nov; 32(7):1473-6. PubMed ID: 11119794
[No Abstract] [Full Text] [Related]
14. Converting renal transplant patients maintained on Sandimmune to a new microemulsion formulation, Sandimmune Neoral.
Chu SH; Pang ST; Chiang YJ; Chuang CK; Chen HW; Chen CS; Chou CC; Huang CC
Transplant Proc; 1998 Nov; 30(7):3521-3. PubMed ID: 9838543
[No Abstract] [Full Text] [Related]
15. Safety and tolerability of CyA microemulsion formulation (Sandimmun Neoral) in stable renal transplant patients after 24 months of treatment. German Neoral Study Group.
Offermann G; Korn A
Transplant Proc; 1996 Aug; 28(4):2204-6. PubMed ID: 8769201
[No Abstract] [Full Text] [Related]
16. Cyclosporine microemulsion formulation (Neoral) in transplantation: pharmacokinetic/pharmacodynamic relationships.
Mueller EA; Niese D; Mellein B
Transplant Proc; 1998 Aug; 30(5):1694-6. PubMed ID: 9723247
[No Abstract] [Full Text] [Related]
17. A meta-analysis to assess the safety and tolerability of two formulations of cyclosporine: Sandimmune and Neoral.
Shah MB; Martin JE; Schroeder TJ; First MR
Transplant Proc; 1998 Dec; 30(8):4048-53. PubMed ID: 9865291
[No Abstract] [Full Text] [Related]
18. Relationship between maintenance dose of cyclosporine and long-term kidney graft survival. Collaborative Transplant Study.
Opelz G
Transplant Proc; 1998 Aug; 30(5):1716-7. PubMed ID: 9723253
[No Abstract] [Full Text] [Related]
19. Cyclosporine lymphocyte level and lymphocyte count: new guidelines for tailoring immunosuppressive therapy.
Barbari A; Stephan A; Masri M; Mourad N; Kamel G; Kilani H; Karam A; Daya IA
Transplant Proc; 2003 Nov; 35(7):2742-4. PubMed ID: 14612101
[No Abstract] [Full Text] [Related]
20. Conversion from regular cyclosporine to microemulsion cyclosporine following heart transplantation.
Heroux AL; LeBlanc MH; Beaudoin D; Simard S; Coulombe DA; Gleeton O; Lemieux MD; Doyle DP
Transplant Proc; 1996 Dec; 28(6):3145-8. PubMed ID: 8962219
[No Abstract] [Full Text] [Related]
[Next] [New Search]
